Skip to content

The Potential Use of Dimethyltryptamine against Ischemia-reperfusion Injury of the Brain

Attila Kovacs, Anna Mathe, Ede Frecska

Journal of Neuroscience and Neurological Disorders April 19, 2024 Peer reviewed DOI: 10.29328/journal.jnnd.1001097

Summary

The activation of the sigma-1 receptor (Sig1-R) shows potential in ameliorating ischemia-reperfusion injury (IRI), a significant issue in emergency medicine. N, N-dimethyltryptamine (DMT) is identified as an endogenous agonist of Sig1-R, which may enhance mitochondrial respiration and endoplasmic reticulum function during cellular stress. The findings suggest that DMT could play a protective role against IRI in conditions like stroke or cardiac arrest.

Study at a glance

Key finding DMT may have therapeutic potentials against different components and types of ischemia-reperfusion injuries.

Abstract

Ischemia-Reperfusion Injury (IRI) is the outcome of two intertwined pathological processes resulting from the shortage of blood flow to tissues and the subsequent restoration of circulation to a previously ischemic area. IRI (sometimes just one side of the dyad) remains one of the most challenging problems in several branches of emergency medicine. Mitochondrial and endoplasmic reticulum dysfunction is a crucial pathological factor involved in the development of IRI. The sigma-1 receptor (Sig1-R) is an intracellular chaperone molecule located between the mitochondria and endoplasmic reticulum with an apparent physiological role in regulating signaling between these cell organelles and serves as a safety mechanism against cellular stress. Therefore, amelioration of IRI is reasonably expected by the activation of the Sig1-R chaperone. Indeed, under cellular stress, Sig1-R agonists improve mitochondrial respiration and optimize endoplasmic reticulum function by sustaining high-energy phosphate synthesis. The discovery that N, N-dimethyltryptamine (DMT) is an endogenous agonist of the Sig1-R may shed light on yet undiscovered physiological mechanisms and therapeutic potentials of this controversial hallucinogenic compound. In this article, the authors briefly overview the function of Sig1-R in cellular bioenergetics with a focus on the processes involved in IRI and summarize the results of their in vitro and in vivo DMT studies aiming at mitigating IRI. The authors conclude that the effect of DMT may involve a universal role in cellular protective mechanisms suggesting therapeutic potentials against different components and types of IRIs emerging in local and generalized brain ischemia after stroke or cardiac arrest.

Comments

No comments yet.

Log in to comment